Participants began with an average HbA1c level of 8.1%. After three months, people who used Omnipod 5 improved HbA1c by an average of 0.8% compared to those using MDI plus CGM. For those with an HbA1c ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

Insulet (PODD) announced its revolutionary Omnipod 5 Automated Insulin Delivery System is now available in Australia and will soon be offered ...

Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.

Corporation shared new Omnipod 5 clinical data from its RADIANT study. Results from this multinational randomized controlled ...

Insulet today announced that it's bringing its automated insulin delivery technology to a range of new geographies.

Insulet (Nasdaq:PODD) announced today that SVP and Chief Technology Officer Mark Field is departing the company.

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland. Omnipod 5 is now commercially available in Australia ...